214 related articles for article (PubMed ID: 11730261)
1. Therapy of male osteoporosis with parathyroid hormone.
Bilezikian JP; Kurland ES
Calcif Tissue Int; 2001 Oct; 69(4):248-51. PubMed ID: 11730261
[TBL] [Abstract][Full Text] [Related]
2. Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers.
Kurland ES; Cosman F; McMahon DJ; Rosen CJ; Lindsay R; Bilezikian JP
J Clin Endocrinol Metab; 2000 Sep; 85(9):3069-76. PubMed ID: 10999788
[TBL] [Abstract][Full Text] [Related]
3. The potential of parathyroid hormone as a therapy for osteoporosis.
Rubin MR; Bilezikian JP
Int J Fertil Womens Med; 2002; 47(3):103-15. PubMed ID: 12081255
[TBL] [Abstract][Full Text] [Related]
4. Alendronate stimulation of nocturnal parathyroid hormone secretion: a mechanism to explain the continued improvement in bone mineral density accompanying alendronate therapy.
Greenspan SL; Holland S; Maitland-Ramsey L; Poku M; Freeman A; Yuan W; Kher U; Gertz B
Proc Assoc Am Physicians; 1996 May; 108(3):230-8. PubMed ID: 8774056
[TBL] [Abstract][Full Text] [Related]
5. Parathyroid hormone versus bisphosphonate treatment on bone mineral density in osteoporosis therapy: a meta-analysis of randomized controlled trials.
Shen L; Xie X; Su Y; Luo C; Zhang C; Zeng B
PLoS One; 2011; 6(10):e26267. PubMed ID: 22022584
[TBL] [Abstract][Full Text] [Related]
6. Parathyroid Hormone Plus Alendronate in Osteoporosis: A Meta-Analysis of Randomized Controlled Trials.
Wang C; Zhang G; Gu M; Fan J; Chen J; Zhang G; Li B
J Invest Surg; 2015; 28(6):309-16. PubMed ID: 26270229
[TBL] [Abstract][Full Text] [Related]
7. A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis.
Hodsman AB; Fraher LJ; Watson PH; Ostbye T; Stitt LW; Adachi JD; Taves DH; Drost D
J Clin Endocrinol Metab; 1997 Feb; 82(2):620-8. PubMed ID: 9024265
[TBL] [Abstract][Full Text] [Related]
8. Does bone resorption inhibition affect the anabolic response to parathyroid hormone?
Martin TJ
Trends Endocrinol Metab; 2004 Mar; 15(2):49-50. PubMed ID: 15080150
[TBL] [Abstract][Full Text] [Related]
9. Intermittent parathyroid hormone therapy to increase bone formation.
Thomas T
Joint Bone Spine; 2006 May; 73(3):262-9. PubMed ID: 16563840
[TBL] [Abstract][Full Text] [Related]
10. ALX 111: ALX1-11, parathyroid hormone (1-84) - NPS Allelix, PREOS, PTH, recombinant human parathyroid hormone, rhPTH (1-84).
Adis International Ltd
Drugs R D; 2003; 4(4):231-5. PubMed ID: 12848587
[TBL] [Abstract][Full Text] [Related]
11. Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal.
Cosman F; Nieves J; Woelfert L; Formica C; Gordon S; Shen V; Lindsay R
J Bone Miner Res; 2001 May; 16(5):925-31. PubMed ID: 11341338
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate.
Rittmaster RS; Bolognese M; Ettinger MP; Hanley DA; Hodsman AB; Kendler DL; Rosen CJ
J Clin Endocrinol Metab; 2000 Jun; 85(6):2129-34. PubMed ID: 10852440
[TBL] [Abstract][Full Text] [Related]
13. Parathyroid hormone and parathyroid hormone-related protein analogs as therapies for osteoporosis.
Augustine M; Horwitz MJ
Curr Osteoporos Rep; 2013 Dec; 11(4):400-6. PubMed ID: 24078470
[TBL] [Abstract][Full Text] [Related]
14. Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial.
Lane NE; Sanchez S; Modin GW; Genant HK; Pierini E; Arnaud CD
J Bone Miner Res; 2000 May; 15(5):944-51. PubMed ID: 10804025
[TBL] [Abstract][Full Text] [Related]
15. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis.
Finkelstein JS; Hayes A; Hunzelman JL; Wyland JJ; Lee H; Neer RM
N Engl J Med; 2003 Sep; 349(13):1216-26. PubMed ID: 14500805
[TBL] [Abstract][Full Text] [Related]
16. Parathyroid hormone(1-84) treatment of postmenopausal women with low bone mass receiving hormone replacement therapy.
Fogelman I; Fordham JN; Fraser WD; Spector TD; Christiansen C; Morris SA; Fox J
Calcif Tissue Int; 2008 Aug; 83(2):85-92. PubMed ID: 18626566
[TBL] [Abstract][Full Text] [Related]
17. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis.
Black DM; Greenspan SL; Ensrud KE; Palermo L; McGowan JA; Lang TF; Garnero P; Bouxsein ML; Bilezikian JP; Rosen CJ;
N Engl J Med; 2003 Sep; 349(13):1207-15. PubMed ID: 14500804
[TBL] [Abstract][Full Text] [Related]
18. [Parathyroid and bone. Role of parathyroid hormone in the treatment of osteoporosis].
Nakamura T
Clin Calcium; 2007 Dec; 17(12):1823-9. PubMed ID: 18057656
[TBL] [Abstract][Full Text] [Related]
19. Parathyroid hormone--a drug for orthopedic surgery?
Skripitz R; Aspenberg P
Acta Orthop Scand; 2004 Dec; 75(6):654-62. PubMed ID: 15762254
[TBL] [Abstract][Full Text] [Related]
20. Short-term, high-dose parathyroid hormone-related protein as a skeletal anabolic agent for the treatment of postmenopausal osteoporosis.
Horwitz MJ; Tedesco MB; Gundberg C; Garcia-Ocana A; Stewart AF
J Clin Endocrinol Metab; 2003 Feb; 88(2):569-75. PubMed ID: 12574182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
